The present invention provides a valve material having synergistic anti-coagulation and anti-calcification functions and a preparation method therefor. The preparation method comprises the following steps: performing glutaraldehyde cross-linking treatment on an animal-derived biological valve material; immersing the treated valve material in a blocking solution containing an amine compound for 0.5-6 h, thereby blocking the remaining aldehyde groups after glutaraldehyde cross-linking; then placing the valve material into a reaction solution containing an anticoagulant and a cross-linking agent, and performing cross-linking treatment for 6-24 h at 4° C.-37° C.; and finally washing and obtaining the valve material, and storing the valve material in a mixed solvent of glutaraldehyde or isopropyl alcohol/glycerol. The method can effectively solve the problem of calcification and thrombosis caused by residual aldehyde groups in a valve material prepared by the existing method. The valve material prepared by the present method can be used as a valve material required for aortic valve, pulmonary valve, venous valve, mitral valve and tricuspid valve replacement.

The invention provides a highly versatile system to promote vascularization in ischemic tissue. The system is composed of a fully defined, customizable hydrogel loaded with a potent cocktail of proangiogenic growth factors. The hydrogel's mechanical, degradation, and factor release behavior can be tailored to the specifications of any given target tissue or ischemic disease state. The growth factor cocktail can be optimized for maximal vessel density or size to meet the perfusion specifications required by the tissue. The embodiments of the disclosure concern methods and compositions of the system, with examples of preparation for both injectable and implantable delivery modes.

Polymers suitable for forming carbon nanotube-functionalized reverse thermal gel compositions, compositions including the polymers, and methods of forming and using the polymers and compositions are disclosed. The compositions have reverse thermal gelling properties and transform from a liquid/solution to a gel—e.g., near or below body temperature. The polymers and compositions can be injected into or proximate an area in need of treatment.

This invention discloses an implant for regeneration of tissue with lesions, comprising a mixture with different types of cells, particularly, mesenchymal stem cells (MSC), endothelial cells, and specific functional cells according to the nature and function of the tissue, included into the biocompatible polymeric matrix, where the cells may or may not be organized in a specific way. This innovation also discloses a method to manufacture the implant. The implant of the present invention is useful for replacement or regeneration of animal and human tissues.

A cardiovascular fibrous implant for rebuilding elastin and the use of such an implant, wherein the implant is comprised of fibers forming a network, and wherein the fibers comprised in said network have a fiber diameter of 150 μm or less.

Provided is a cardiovascular implant based on in-situ regulation of immune response and a method for making the same, belonging to the technical field of biomedicine. The cardiovascular implant includes a cardiovascular implant body and H4000-CD25/dcas9 sustained-release nanoparticles modified on the cardiovascular implant body; the H4000-CD25/dcas9 sustained-release nanoparticles include an H4000 plasmid nanocarrier (Engreen), an anti-CD25 antibody, and a dcas9 plasmid sequence; a method for preparing the cardiovascular implant includes: constructing a cardiovascular implant body, preparing an H4000-CD25 nanotransfection vector, preparing H4000-CD25/dcas9 sustained-release nanoparticles, and conjugating the H4000-CD25/dcas9 sustained-release nanoparticles on the cardiovascular implant body. The present disclosure aims to construct a cardiovascular implant modified with the H4000-CD25/dcas9 sustained-release nanoparticles, which may induce nerve fiber ingrowth into engineered blood vessels; with the regulation ability of Treg cells on immune response, antithrombotic function of the cardiovascular implant is improved and in-situ regeneration of the cardiovascular implant is promoted.

Provided are methods for improving cell-based therapies by co-administration with an agent that increases the production and or levels of epoxygenated fatty acids, as well as kits, stents and patches for co-administering stem cells with an agent that increases the production and/or levels of epoxygenated fatty acids.

A biocompatible adhesive is disclosed. The biocompatible adhesive includes a substrate and a plurality of micro-scale elements extending from a surface of the substrate having a length selected to puncture a layer of a target tissue or target material. At least some of the micro-scale elements include at least one protrusion dimensioned to anchor the biocompatible adhesive to the target tissue or target material. A medical device assembly is also disclosed. The medical device assembly includes the biocompatible adhesive coupled to a surface of a component of the medical device assembly and positioned to attach the medical device assembly to the target tissue or target material. A method of facilitating attachment of a medical device assembly to a target tissue is also disclosed. A method of facilitating treatment of a wound is also disclosed.

Cyclic peptide pro-gelator compositions, and methods of therapeutic use, which assemble into macromolecular hydrogel when administered through cleavage by endogenous enzymes upregulated at a site of tissue injury, such as a myocardial infarction.

A biomimetic, polymeric composite biomaterial designed as a heart valve leaflet substitute that can be used for heart valve repair and/or to fabricate a new-generation of durable heart valve prosthesis.